Celator Pharmaceuticals (NASDAQ:CPXX) has tumbled 0.26% during the past week, however, the bigger picture is still very bullish; the stocks have advanced and posted positive gains of 78.46% in the last four weeks. In the past week, the company has outperformed the S&P 500 by 0.93% and the outperformance has advanced to 76.83% for the last 4 weeks period.
Celator Pharmaceuticals (NASDAQ:CPXX): During Fridays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $30.07 and $29.98 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $30.20. The buying momentum continued till the end and the stock did not give up its gains. It closed at $30.16, notching a gain of 0.23% for the day. The total traded volume was 2,107,829 . The stock had closed at $30.09 on the previous day.
On the companys insider trading activities, Morenstein Scott D, director of Celator Pharmaceuticals Inc, executed a transaction worth $9,350 on December 3, 2015. A total of 5,000 shares were purchased at an average price of $1.87. The Insider information was divulged by the Securities and Exchange Commission in a Form 4 filing. The information is based on open market trades at the market prices.Option exercises are not covered.
Many analysts have stated their opinion on the company shares. Equity analysts at the Brokerage firm Stifel Nicolaus downgrades its rating on Celator Pharmaceuticals (NASDAQ:CPXX). The rating major has initiated the coverage with hold rating on the shares. Earlier, the shares were rated a Buy by the brokerage firm. The rating by the firm was issued on June 1, 2016. Currently the company Insiders own 3.4% of Celator Pharmaceuticals shares according to the proxy statements. Institutional Investors own 45.45% of Celator Pharmaceuticals shares.
Celator Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing products to cure cancer. Celators technology platform, CombiPlex, offers the rational design and rapid evaluation of combinations incorporating traditional chemotherapies, as well as molecularly targeted agents to deliver anti-cancer activity. The Companys products are in research and development phases. Celators lead product is CPX-351, a liposomal formulation of cytarabine:daunorubicin for the treatment of acute myeloid leukemia. The Company owns worldwide development and commercialization rights to CPX-351. The Companys other pipeline products includes CPX-1, a liposomal formulation of irinotecan:floxuridine for the treatment of colorectal cancer, and a preclinical stage product candidate, CPX-8, a hydrophobic docetaxel prodrug nanoparticle formulation.